Clinical features of patients hospitalised with COVID-19 from February to October 2020, during the early waves of the pandemic in New Zealand.


Journal

The New Zealand medical journal
ISSN: 1175-8716
Titre abrégé: N Z Med J
Pays: New Zealand
ID NLM: 0401067

Informations de publication

Date de publication:
01 04 2022
Historique:
entrez: 21 6 2022
pubmed: 22 6 2022
medline: 24 6 2022
Statut: epublish

Résumé

As New Zealand transitions towards endemic SARS-CoV-2, understanding patient factors predicting severity, as well as hospital resourcing requirements will be essential for future planning. We retrospectively enrolled patients hospitalised with COVID-19 from 26 February to 5 October 2020 as part of the COVID-19 HospitalisEd Patient SeverIty Observational Study NZ (COHESION). Data on demographics, clinical course and outcomes were collected and analysed as a descriptive case series. Eighty-four patients were identified across eight district health boards. Forty-one (49%) were male. The median age was 58 years [IQR: 41.7-70.3 years]. By ethnicity, hospitalisations included 38 NZ European (45%), 19 Pasifika (23%), 13 Māori (15%), 12 Asian (14%) and 2 Other (2%). Pre-existing co-morbidities included hypertension (26/82, 32%), obesity (16/66, 24%) and diabetes (18/81, 22%). The median length of stay was four days [IQR: 2-15 days]. Twelve patients (12/83, 14%) were admitted to an intensive care unit or high dependency unit (ICU/HDU). Ten (10/83, 12%) patients died in hospital of whom seven (70%) were not admitted to ICU/HDU; the median age at death was 83 years. Despite initially low case numbers in New Zealand during 2020, hospitalisation with COVID-19 was associated with a high mortality and hospital resource requirements.

Identifiants

pubmed: 35728191

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-130

Déclaration de conflit d'intérêts

Nil.

Auteurs

Aliya Bryce (A)

Microbiology Department, Counties-Manukau District Health Board, Auckland, New Zealand.

Lydia Foley (L)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Juliette Phillipson (J)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Sandy Slow (S)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Malina Storer (M)

Respiratory Medicine Department, Canterbury District Health Board, New Zealand.

Jonathan Williman (J)

Department of Population Health, University of Otago, Christchurch, New Zealand.

Richard Beasley (R)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Hasan Bhally (H)

Infectious Diseases Department, Waitematā District Health Board, Auckland, New Zealand.

Cat L Chang (CL)

Respiratory Medicine Department, Waikato District Health Board, Hamilton, New Zealand.

Jack Dummer (J)

Department of Medicine, University of Otago, Dunedin, New Zealand; Respiratory Medicine Department, Southern District Health Board, Dunedin, New Zealand.

Michael Epton (M)

Respiratory Medicine Department, Canterbury District Health Board, New Zealand.

Mary Furniss (M)

Infectious Diseases Department, Auckland District Health Board, Auckland, New Zealand.

Kathryn Gracie (K)

Respiratory Medicine Department, Waikato District Health Board, Hamilton, New Zealand.

Robert J Hancox (RJ)

Respiratory Medicine Department, Waikato District Health Board, Hamilton, New Zealand.

Thomas Hills (T)

Medical Research Institute of New Zealand, Wellington, New Zealand; Infectious Diseases Department, Auckland District Health Board, Auckland, New Zealand.

Stephen Hogg (S)

Infectious Diseases Department, Hutt Valley District Health Board, Hutt Valley, New Zealand.

Sandra Hotu (S)

Respiratory Medicine Department, Auckland District Health Board, Auckland, New Zealand.

Nethmi Kearns (N)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Susan Morpeth (S)

Microbiology Department, Counties-Manukau District Health Board, Auckland, New Zealand.

David Murdoch (D)

Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.

Nigel Raymond (N)

Infectious Diseases Department, Capital and Coast District Health Board, Wellington, New Zealand.

Stephen Ritchie (S)

Infectious Diseases Department, Auckland District Health Board, Auckland, New Zealand.

Conroy Wong (C)

Respiratory Medicine Department, Counties Manukau-District Health Board, Auckland, New Zealand.

Michael J Maze (MJ)

Department of Medicine, University of Otago, Christchurch, New Zealand; Respiratory Medicine Department, Canterbury District Health Board, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH